| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/22/2011 | US20110230470 Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors |
| 09/22/2011 | US20110230464 Purine derivatives useful as p13 kinase inhibitors |
| 09/22/2011 | US20110230462 Pyrrolopyrazine Kinase Inhibitors |
| 09/22/2011 | US20110230459 Lactam acetamides as calcium channel blockers |
| 09/22/2011 | US20110230458 Phenyl-heteroaryl derivatives and methods of use thereof |
| 09/22/2011 | US20110230457 Substituted Isoquinolinones and Quinazolinones |
| 09/22/2011 | US20110230456 Nitridoosmium(VI) Complexes for Treatment of Cancer |
| 09/22/2011 | US20110230451 Identification and use of compounds that affect the fidelity of eukaryotic translation initiation codon selection |
| 09/22/2011 | US20110230446 Cathepsin cysteine protease inhibitors |
| 09/22/2011 | US20110230444 Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor |
| 09/22/2011 | US20110230443 IMIDAZO[1,2-a] PYRIDINYL BISPHOSPHONATES |
| 09/22/2011 | US20110230442 Na channels, disease, and related assays and compositions |
| 09/22/2011 | US20110230441 Stable bortezomib formulations |
| 09/22/2011 | US20110230433 Compositions and methods for treatment of cancer |
| 09/22/2011 | US20110230430 Saponin extract from saponaria spp. and uses thereof |
| 09/22/2011 | US20110230423 Therapy and medicament using integrin ligands for treating cancer |
| 09/22/2011 | US20110230422 Purging of an ex vivo hematopoietic stem cell culture of cancer cells |
| 09/22/2011 | US20110230421 Fusion proteins of apoptin-protein transduction domain of carboxyl-terminus of ec-sod |
| 09/22/2011 | US20110230420 Releasable conjugates for nucleic acids delivery systems |
| 09/22/2011 | US20110230419 Iap binding compounds |
| 09/22/2011 | US20110230418 Anticancer Agent |
| 09/22/2011 | US20110230414 Pyrrolopyrazine Kinase Inhibitors |
| 09/22/2011 | US20110230397 Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer |
| 09/22/2011 | US20110229944 FAD4, FAD5, FAD5-2, AND FAD6, Novel Fatty Acid Desaturase Family Members and Uses Thereof |
| 09/22/2011 | US20110229581 Releasable cationic lipids for nucleic acids delivery systems |
| 09/22/2011 | US20110229577 Biologically active silicic acid |
| 09/22/2011 | US20110229576 Hollow silica nanospheres and methods of making same |
| 09/22/2011 | US20110229573 Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form |
| 09/22/2011 | US20110229572 Delivery of drug combinations |
| 09/22/2011 | US20110229560 Nlrc5 as a target for immune therapy |
| 09/22/2011 | US20110229554 INTRAVENOUS FORMULATIONS OF COENZYME Q10 (CoQ10) AND METHODS OF USE THEREOF |
| 09/22/2011 | US20110229552 NOVEL mRNA SPLICE VARIANT OF THE DOUBLECORTIN-LIKE KINASE GENE AND ITS USE IN DIAGNOSIS AND THERAPY OF CANCERS OF NEUROECTODERMAL ORIGIN |
| 09/22/2011 | US20110229550 Acid-Degradable and Bioerodible Modified Polyhydroxylated Materials |
| 09/22/2011 | US20110229525 Modulation of cytokine signaling |
| 09/22/2011 | US20110229524 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of Gastric Cancer and other cancers |
| 09/22/2011 | US20110229521 Nutritional support of the immune system during anti-cancer treatment |
| 09/22/2011 | US20110229517 System and process for producing multi-component biopharmaceuticals |
| 09/22/2011 | US20110229510 Glycopeptide constructs and uses thereof |
| 09/22/2011 | US20110229506 Method for cancer immunotherapy |
| 09/22/2011 | US20110229505 Methods for the diagnosis and treatment of cancer based on AVL9 |
| 09/22/2011 | US20110229504 Novel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| 09/22/2011 | US20110229503 Vaccination against malignant melanoma using bcg and/or vaccinia |
| 09/22/2011 | US20110229502 Ablative immunotherapy |
| 09/22/2011 | US20110229494 Teneurin and cancer |
| 09/22/2011 | US20110229493 Neuregulin antagonists and use thereof in treating cancer |
| 09/22/2011 | US20110229492 Compositions and methods for diagnosing, treating, and preventing prostate conditions |
| 09/22/2011 | US20110229491 Minichromosome maintenance complex interacting protein involved in cancer |
| 09/22/2011 | US20110229490 Lyophilized Formulations of Engineered Anti-IL-23p19 Antibodies |
| 09/22/2011 | US20110229488 Progastrin and liver pathologies |
| 09/22/2011 | US20110229486 Monoclonal Antibodies Against NKG2A |
| 09/22/2011 | US20110229485 Inhibition of the nt-3:trkc bound and its application to the treatment of cancer such as neuroblastoma |
| 09/22/2011 | US20110229483 Tumor angiogenesis associated genes and a method for their identification |
| 09/22/2011 | US20110229481 Cancer-associated antigen analogue peptides and uses thereof |
| 09/22/2011 | US20110229480 Pta072 protein |
| 09/22/2011 | US20110229479 Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma |
| 09/22/2011 | US20110229478 Erbb3 based methods and compositions for treating neoplasms |
| 09/22/2011 | US20110229476 Monospecific and multispecific antibodies and method of use |
| 09/22/2011 | US20110229475 Novel compounds |
| 09/22/2011 | US20110229473 Methods for using taci-immunoglobulin fusion proteins |
| 09/22/2011 | US20110229469 Methods for the treatment of cancer |
| 09/22/2011 | US20110229468 Targeting pax2 for the treatment of breast cancer |
| 09/22/2011 | US20110229467 Targeting pax2 for the treatment of breast cancer |
| 09/22/2011 | US20110229466 Vascular endothelial growth factor 2 |
| 09/22/2011 | US20110229463 Recombinant anti-epidermal growth factor receptor antibody compositions |
| 09/22/2011 | US20110229462 Hepatocyte Growth Factor (HGF) Binding Proteins |
| 09/22/2011 | US20110229461 PD-1 Antibodies |
| 09/22/2011 | US20110229456 Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| 09/22/2011 | US20110229443 Composition for Cancer Prevention or Treatment Containing as Active Ingredient Plant Stem Cell Line Dervied from Cambium of Panax Ginseng Including Wild Ginseng or Ginseng |
| 09/22/2011 | US20110229418 Compositions and Methods of Treating and Preventing Lung Cancer |
| 09/22/2011 | US20110229411 Use of p2x7 pathway for assessing the sensitivity of a subject to a cancer treatment |
| 09/22/2011 | US20110229409 Linkable lewis x analogs |
| 09/22/2011 | US20110229408 Sodium-iodide symporter gene repressor binding site |
| 09/22/2011 | US20110229407 Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof |
| 09/22/2011 | US20110229406 Material and methods for treating or preventing HER-3 associated diseases |
| 09/22/2011 | US20110226650 Antibody formulation |
| 09/22/2011 | DE102010012234A1 Pharmaceutical combination preparation, useful to treat cancer, preferably to reduce e.g. nephrotoxicity of cisplatin or platinum complex analog, comprises 12-imidazolyl-1-dodecanol and cisplatin or a platinum complex analog |
| 09/22/2011 | DE102010012232A1 New imidazole useful in pharmaceutical preparation e.g. for prevention or treatment of cancer diseases, pathological effects of alcohol misuse, viral hepatitis, steatohepatitis, acute and chronic pancreatitis, toxic renal diseases |
| 09/22/2011 | CA2797295A1 Ganglioside micelles as a delivery system for hidrophobic drugs |
| 09/22/2011 | CA2793838A1 Integrin interaction inhibitors for the treatment of cancer |
| 09/22/2011 | CA2793594A1 Method and process for preparation and production of deuterated .omega.-diphenylurea |
| 09/22/2011 | CA2793527A1 Novel methods for targeting cancer stem cells |
| 09/22/2011 | CA2793526A1 Novel compounds and compositions for targeting cancer stem cells |
| 09/22/2011 | CA2793389A1 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers |
| 09/22/2011 | CA2793359A1 Process for the preparation of malic acid salt of sunitinib |
| 09/22/2011 | CA2793311A1 Modulators of hec1 activity and methods therefor |
| 09/22/2011 | CA2793299A1 Morpholinylquinazolines |
| 09/22/2011 | CA2793279A1 Imidazopyrazines |
| 09/22/2011 | CA2793125A1 New enzyme inhibitor compounds |
| 09/22/2011 | CA2793023A1 Cancer therapy with a parvovirus combined with an hdac inhibitor |
| 09/22/2011 | CA2791737A1 Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
| 09/22/2011 | CA2791613A1 Indazole compounds and their uses |
| 09/22/2011 | CA2789857A1 Novel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| 09/21/2011 | EP2366774A2 PUFA polyketide synthase systems and uses thereof |
| 09/21/2011 | EP2366773A2 PUFA polyketide synthase systems and uses thereof |
| 09/21/2011 | EP2366772A2 PUFA polyketide synthase systems and uses thereof |
| 09/21/2011 | EP2366771A2 PUFA polyketide synthase systems and uses thereof |
| 09/21/2011 | EP2366716A2 Combinatorial therapy involving alpha5beta1 antagonists |
| 09/21/2011 | EP2366713A2 Polypeptide variants with altered effector function |
| 09/21/2011 | EP2366712A2 A tumor suppressor designated TS10Q23.3 |
| 09/21/2011 | EP2366711A2 Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer |